A "Function-First" Approach to Identify Regulatory T cell-Targeting Antibodies for Immunotherapy.

ABSTRACT: Despite advances in cancer immunotherapy, treatment response is still highly variable. One contributing factor is the tumor microenvironment and specifically the presence of suppressive immune cells such as regulatory T (Treg) cells. Being able to target these specifically, while leaving effector T-cell populations untouched, is an attractive strategy that may overcome some of these issues, improving responses. To generate antibodies specific for tumor-associated Tregs, lymphocytes were isolated from tumor-bearing mice and panned against the n-CoDeR phage antibody library. Using the target-agnostic F.I.R.S.T. discovery platform, they were evaluated in ex vivo and in vivo models to determine tissue and cell selectivity and specificity and ability to deplete Tregs and elicit tumor control in

SUBMITTER: Cleary KLS 

PROVIDER: S-EPMC12670074 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature